Synaptic Acid Encapsulated with Selenium-Mesoporous Silica Nanocomposite: A Potential Drug in Treating Cardiovascular Disease.

The development of multifunctional nanomaterials can greatly improve therapeutic efficacy in treating disease. In this present study, we report a new class of drug delivery system to maximize the therapeutic potential in treating cardiovascular disease. Synaptic acid encapsulated selenium-mesoporous silica (SA-PSiO2-SeNDs-PEG) nanocomposite was synthesized via the conjugation of synaptic acid (SA) with encapsulated selenium-mesoporous silica. This nanocomposite showed a more stable and sustainable SA release capacity in the delivery system. Furthermore, the treatment of SA-PSiO2-SeNDs-PEG nanocomposite reduced the reactive oxygen species (ROS) stress via the 2′, 7′-dichlorofluorescein diacetate (DCFH-DA) fluorescence intensity measurements in vitro. Furthermore, serum content analysis revealed a drop in the low-density lipoprotein level. The histological analysis resulted in no morphological difference in the mice tissue section treated with SA-PSiO2-SeNDs-PEG nanocomposite as compared to the mice treated with saline solution, signifying no side effects occurred using this drug delivery platform. In short, SA-PSiO2-SeNDs-PEG nanocomposite are novel drug delivery platforms that will be potentiating the treatment of cardiovascular disease with more insights that are elucidated. [ABSTRACT FROM AUTHOR]